Title: Safe Opioid Prescribing: Maximum Benefits and Minimizing Risks
Presenter: James Paul Seale, MD, Professor and Director of Research, Dept. of Family Medicine, Medical Center of Central Georgia and Mercer University School of Medicine, Macon, GA
After completing this training, participants should be able to:
1. Describe negative consequences that may occur in patients who receive prescriptions for opioid medication
2. Perform an initial assessment and baseline measurement of a patient requesting opioid therapy
3. Implement a monitoring framework to protect the safety of patients receiving ongoing opioid therapy
4. Address concerning behaviors of patients on chronic opioid therapy
Accreditation and Designation: The American Academy of Addiction Psychiatry (AAAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
American Academy of Addiction Psychiatry (AAAP) designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In accordance with the American with Disabilities Act, we encourage persons with disabilities to participate in this activity. If you anticipate needing any type of accommodation or have questions about this CME activity, please contact firstname.lastname@example.org.
AAAP’s CME Program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. This information will be disclosed to the audience prior to the activity’s commencement. The speaker has been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. The audience will be informed during the discussion if off-label or investigative drugs uses are presented.
Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Opioid Therapies (grant no. 5H79TI025595) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Funding for this project also was provided by the Rhode Island Department of Health (HEALTH) supported by the Centers for Disease Control and Prevention (CDC), Preventive Health and Health Services Block Grant.